Macrogenics Stock Performance
| MGNX Stock | USD 1.48 0.06 3.90% |
On a scale of 0 to 100, MacroGenics holds a performance score of 3. The company secures a Beta (Market Risk) of 2.51, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MacroGenics will likely underperform. Please check MacroGenics' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether MacroGenics' current price movements will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in MacroGenics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, MacroGenics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | MacroGenics Announces Date of First Quarter 2025 Financial Results MGNX Stock News | 05/06/2025 |
2 | MacroGenics Price Target Lowered by Stifel MGNX Stock News | 05/14/2025 |
3 | Earnings Release Heres Why Analysts Cut Their MacroGenics, Inc. Price Target To US4.50 | 05/16/2025 |
4 | MacroGenics Sees Target Price Cut Amid Pipeline Focus MGNX Stock News | 05/20/2025 |
5 | Analyst Forecasts For MacroGenics, Inc. Are Surging Higher | 05/21/2025 |
6 | MacroGenics SWOT analysis biotech firms stock faces pipeline challenges By Investing.com - Investing.com India | 05/27/2025 |
7 | Disposition of 13332 shares by Jeffrey Peters of MacroGenics subject to Rule 16b-3 | 05/30/2025 |
8 | MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | 06/03/2025 |
9 | MacroGenics, Sagard Healthcare enter into ZYNYZ royalty purchase MGNX | 06/10/2025 |
10 | MacroGenics Downgraded by Wall Street Zen to Sell | 06/30/2025 |
| Begin Period Cash Flow | 101 M | |
| Total Cashflows From Investing Activities | 149.3 M |
MacroGenics | Build AI portfolio with MacroGenics Stock |
MacroGenics Relative Risk vs. Return Landscape
If you would invest 139.00 in MacroGenics on April 20, 2025 and sell it today you would earn a total of 9.00 from holding MacroGenics or generate 6.47% return on investment over 90 days. MacroGenics is currently generating 0.2796% in daily expected returns and assumes 6.127% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than MacroGenics, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MacroGenics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MacroGenics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MacroGenics, and traders can use it to determine the average amount a MacroGenics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0456
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MGNX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.13 actual daily | 54 54% of assets are less volatile |
Expected Return
| 0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average MacroGenics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MacroGenics by adding it to a well-diversified portfolio.
MacroGenics Fundamentals Growth
MacroGenics Stock prices reflect investors' perceptions of the future prospects and financial health of MacroGenics, and MacroGenics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MacroGenics Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (3.23) % | ||||
| Current Valuation | (22.67 M) | ||||
| Shares Outstanding | 63.09 M | ||||
| Price To Earning | (4.54) X | ||||
| Price To Book | 1.19 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 148.34 M | ||||
| Gross Profit | (38.98 M) | ||||
| EBITDA | (57.37 M) | ||||
| Net Income | (66.97 M) | ||||
| Cash And Equivalents | 133.74 M | ||||
| Cash Per Share | 2.18 X | ||||
| Total Debt | 37.46 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | (68.37 M) | ||||
| Earnings Per Share | (0.88) X | ||||
| Market Capitalization | 93.37 M | ||||
| Total Asset | 261.65 M | ||||
| Retained Earnings | (1.17 B) | ||||
| Working Capital | 161.96 M | ||||
| Current Asset | 342.38 M | ||||
| Current Liabilities | 23.29 M | ||||
About MacroGenics Performance
Evaluating MacroGenics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MacroGenics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MacroGenics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 62.33 | 59.22 | |
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.54) | (0.56) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.58) | (0.61) |
Things to note about MacroGenics performance evaluation
Checking the ongoing alerts about MacroGenics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MacroGenics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MacroGenics had very high historical volatility over the last 90 days | |
| MacroGenics may become a speculative penny stock | |
| MacroGenics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 148.34 M. Net Loss for the year was (66.97 M) with loss before overhead, payroll, taxes, and interest of (38.98 M). | |
| MacroGenics currently holds about 133.74 M in cash with (68.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| MacroGenics has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: MacroGenics Downgraded by Wall Street Zen to Sell |
- Analyzing MacroGenics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MacroGenics' stock is overvalued or undervalued compared to its peers.
- Examining MacroGenics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MacroGenics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MacroGenics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MacroGenics' stock. These opinions can provide insight into MacroGenics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.